Undisclosed PSMA TriKE / GT Biopharma - LARVOL DELTA

A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer. (PubMed, Cancer Immunol Res) - "Finally, in vivo testing of PSMA TriKE showed improved tumor control and survival of mice as compared to IL-15 and untreated control groups. In conclusion, PSMA TriKE demonstrates potential as a new therapy for advanced prostate cancer by providing additional signals to NK cells to maximize their anti-tumor potential in prostate cancer, especially in the setting of a hostile TME."

Journal • Trispecific • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • IL15

Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel tri-specific killer engager (AACR 2024) - "PSMA TriKE demonstrates potential in overcoming suppression of NK cells in the TME of mCRPC and is a promising candidate for advanced prostate cancer therapy."

Biomarker • Trispecific • Tumor microenvironment • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • IFNG • IL15 • TNFA

Maximizing NK cell immunotherapy in prostate cancer via TriKEs (SITC 2023) - "Peripheral Blood Mononuclear Cells (PBMCs) from normal donors or prostate cancer patients were either used directly or magnetically enriched for NK cells in assays co-culturing cells with PCa cell lines in the presence or absence of PSMA TriKE or B7H3 TriKE...NK cell cytotoxicity is also improved, even in the presence of enzalutamide resistant lines (figure 1C), hypoxia (figure 1D), or Myeloid Derived Suppressor Cells...Conclusions Our findings indicate that TriKE molecules improve PCa control in several systems and in the presence of varied TME-specific stresses. These pre-clinical studies highlight the potential for using TriKE molecules in the setting of metastatic Prostate Cancer and pave the way for future, targeted, NK cell immunotherapeutic interventions in this setting."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD276 • IL15

Enhancing NK cell function in the ’cold’ tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) (SITC 2022) - "Efficient delivery of IL-15 to NK cells by PSMA-TriKE robustly relieves NK cells from suppression induced by hypoxia and MDSCs. These results demonstrate promising potential of PSMA TriKE in overcoming suppression of NK cells in the TME of mCRPC."

Biomarker • Tumor microenvironment • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • IFNG • IL15 • TNFA

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (GlobeNewswire) - "GT Biopharma...will present two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)....The novel 'PSMA TriKE' induces specific NK cell activation against PSMA-expressing prostate cancer cell lines. The PSMA TriKE sustains NK cell cytolytic capacity even after long term incubation in hypoxia. PSMA TriKE maintains NK cell degranulation after co-culture with MDSC."

Preclinical • Oncology